Logo

GSK's Nucala (mepolizumab) Receives the EC's Approval for the Treatment of Eosinophil-Driven Diseases

Share this
GSK's Nucala (mepolizumab) Receives the EC's Approval for the Treatment of Eosinophil-Driven Diseases

GSK's Nucala (mepolizumab) Receives the EC's Approval for the Treatment of Eosinophil-Driven Diseases

Shots:

  • The approvals are based on the clinical trials to evaluate mepolizumab vs PBO when added to SoC in patients with HES, EGPA & CRSwNP
  • In HES, patients experienced a HES flare (28% vs 56%) @ 32wks. The therapy increased both accrued time in remission & the proportion of patients who achieved remission in patients with EGPA while 70% of patients had a diagnosis of asthma, improvements in the size of nasal polyps @52wks. & in nasal obstruction @49-52wks. along with a reduction in further surgeries @52wks. in patients with CRSwNP
  • Nucala is the 1st anti-IL-5 biologic treatment for HES or CRS with nasal polyps in the EU & is available as a solution in a prefilled pen or syringe or as a powder

Click here to­ read full press release/ article

 Ref: GSK  | Image: GSK 


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions